(Stroke. 1997;28:1066-1072.)
© 1997 American Heart Association, Inc.
Articles |
From the Cardiovascular Research Center, Department of Physiology, Medical College of Wisconsin, and Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wis.
Correspondence to David R. Harder, PhD, Cardiovascular Research Center, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226.
| Abstract |
|---|
|
|
|---|
Methods Primary astrocyte cultures were prepared from 3-day-old rat pups. The cells were labeled with [14C]AA, and the effect of glutamate on the formation of EETs from [14C]AA by cultured astrocytes was studied. The expression of P-450 2C11 protein in the microsomal fractions of cultured astrocytes was assessed by Western blot. In vivo cerebral blood flow measurements were made in adult rats by laser-Doppler flowmetry after administration of glutamate into the subdural space of the rat before and after treatment with miconazole.
Results Glutamate treatment (100 µmol/L for 30 minutes) induced a threefold increase in the formation of EETs from [14C]AA by cultured astrocytes, and the increase was inhibited by miconazole (20 µmol/L), an inhibitor of P-450 AA epoxygenase. Treatment with glutamate (100 µmol/L) for 12 hours increased the expression of P-450 2C11 protein in the microsomal fraction of cultured astrocytes. The response of laser-Doppler cerebral blood flow to administration of glutamate (500 µmol/L) into the subdural space of the rat was significantly attenuated after treatment with miconazole (20 µmol/L for 30 minutes).
Conclusions These findings suggest a role for a P-450 AA epoxygenase in astrocytes in the coupling between the metabolic activity of neurons and regional blood flow in the brain.
Key Words: astrocytes rats cerebral blood flow glutamates
| Introduction |
|---|
|
|
|---|
Glutamate is the most extensively distributed excitatory amino acid neurotransmitter in the cerebral cortex.4 While glutamate has no apparent action on cerebral arterial muscle or other cell types in the vascular wall,5 6 when applied to the surface of the brain in vivo it induces dilation of cerebral vessels.7 Such findings have led to the hypothesis that "spillover" of glutamate during neuronal activation initiates release of vasodilator metabolites, leading to a regional increase in CBF.
Astrocytes possess receptors for glutamate8 and constitute the most numerous cell type in the central nervous system.4 Previous reports have shown that glutamate induces release of AA from membrane-bound pools in astrocytes.9 We have recently cloned and sequenced a cytochrome P-450 (P-450) cDNA from cortical astrocytes, which is homologous to a previously sequenced P-450 2C11 cDNA from rat liver.10 This P-450 2C11 codes for an epoxygenase, which metabolizes AA to 5,6-, 8,9-, 11,12-, and 14,15-EETs.10 11,12- and 14,15-EETs dilate cerebral arteries by increasing K+ channel activity and hyperpolarizing the vascular muscle membrane.10 11 12 Inhibition of EET formation results in a marked reduction in baseline CBF13 and therefore must be considered a primary candidate involved in the physiological regulation of nutritive blood flow. The purpose of the present study was to test the hypothesis that glutamate-induced dilation of cerebral arterioles is mediated in part by the formation and release of EETs from perivascular astrocytes. We describe a combined in vitro and in vivo approach to demonstrate the action of glutamate on the formation and release of EETs and on the expression of P-450 2C11 epoxygenase by rat cortical astrocytes.
| Materials and Methods |
|---|
|
|
|---|
Astrocytes were identified by indirect immunocytochemistry with the use of a monoclonal antiglial fibrillary acidic protein mouse IgG (Boehringer Mannheim) as the primary antibody and fluorescein isothiocyanateconjugated goat anti-mouse IgG (Boehringer Mannheim) as the secondary antibody. Approximately 3x104 cells in 1.5 mL medium were seeded on 22x22-mm coverslips (VWR) in a 35x10-mm Petri dish (Costar) and incubated at 37°C in 95% air/5% CO2 for 24 to 48 hours. Coverslips were then rinsed with DPBS containing Ca2+ and Mg2+ (Gibco BRL), and cells were fixed in cold methanol for 5 minutes at -20°C. Cells were permeabilized in 0.25% Triton X-100 in DPBS (Sigma) for 2 minutes at room temperature, blocked with 3% normal goat serum in DPBS for 30 minutes at room temperature, and incubated with 100 µL of 5 µg/mL (1:4 dilution in 0.1% normal goat serum) primary antibody for 1 hour at room temperature and finally with 100 µL of 2.68 µg/mL (1:500 dilution in 0.5% BSA/DPBS) of secondary antibody for 1 hour at room temperature in the dark. Coverslips were then washed with DPBS and mounted on a 25x75-mm slide (VWR) with a drop of histological mounting media. Slides were visualized with the aid of a Nikon Diaphot inverted microscope equipped for epifluorescence. The excitation wavelength was selected by narrow band filters (10 nm) centered at 495 nm, and images were acquired at a 525-nm emission frequency with a silicon-intensified CCD camera (Hamamatsu Photonics).
Assay of AA Metabolism
Confluent 10- to 14-day-old primary cultures of astrocytes were
prepared as described above, washed three times in DMEM, and incubated
overnight with 0.45 µCi of [14C]AA (57.0 mCi/mmol; Du
Pont) added to 14 mL of 0.05% fatty acidfree BSA in DMEM. The medium
was decanted, and cells were washed three times with DMEM and incubated
further for 30 minutes. The conditioned DMEM was collected, and cells
were scraped off the flask and homogenized in ice-cold PBS.
In the experimental cultures, cells were washed three times in DMEM and
incubated with glutamate in DMEM (100 µmol/L) for 30 minutes at
37°C before homogenization. In some experiments,
miconazole (20 µmol/L) was added to the media 30 minutes before
glutamate treatment. Control cultures were incubated with an equal
volume of vehicle in DMEM. Acid lipids from both the cell
homogenate and the medium were extracted twice with 3 mL of
ethyl acetate, back extracted with 1 mL of distilled water, evaporated
to dryness under nitrogen, and reconstituted in 0.5 mL of ethanol.
Cell- and medium-associated products were separated by rpHPLC, as
described previously.10 Briefly, AA products were
separated with the use of a 2.1-mmx25-cm C-18 rpHPLC column (Supelco
LC-18) and a linear solvent gradient ranging from 30:70:1
acetonitrile/water/acetic acid (vol/vol/vol) to 100:1
acetonitrile/acetic acid (vol/vol) over 50 minutes at a flow rate of
0.5 mL/min. AA metabolites were monitored with an on-line radioactive
flow detector (model 171, Beckman System Gold). Products were
identified by coelution with authentic standards.
Protocol 2: Effect of Glutamate on Expression of P-450 2C11 Protein
in Astrocytes
Western Blot
Western blots of microsomes prepared from astrocytes cultured
from the hippocampus of the rat brain were performed with the use of a
polyclonal antibody raised in our laboratory against peptide sequences
derived from P-450 2C11, as described previously.10
Confluent monolayers (10 to 14 days) of primary cultures of astrocytes
were incubated with 100 µmol/L glutamate or the same volume of
vehicle in the feeding medium for 24 hours at 37°C. Cells were washed
three times with DPBS and scraped for preparation of microsomes by
differential centrifugation, as previously
described.10 Microsomal proteins (20 µg) were separated
on a 7.5% sodium dodecyl sulfatepolyacrylamide gel
and transferred electrophoretically to a 0.2-µm supported
nitrocellulose membrane (Bio-Rad) in a transfer buffer (25 mmol/L
Tris, 192 mmol/L glycine, pH 8.3) containing 20% vol/vol methanol
at room temperature for 1 hour at 100 V. The membrane was blocked in a
TBS-T buffer (50 mmol/L Tris, 0.2 mol/L NaCl, 0.08% Tween-20, pH
7.5) containing 5% nonfat dry milk at 4°C overnight. Then the
membrane was incubated with P-450 2C11 antibody (1:3000 dilution in
TBS-T containing 2% nonfat dry milk) for 2 hours at room temperature.
The membrane was washed with TBS-T three times and incubated with the
secondary antibody. Goat anti-rabbit IgG conjugated with horseradish
peroxidase (Bio-Rad) was used as the secondary antibody. Incubations
were performed at room temperature for 30 minutes at a 1:1000 dilution
of the secondary antibody in TBS-T containing 2% nonfat dry milk.
Avidinhorseradish peroxidase IgG (Bio-Rad) was included at 1:3000
dilution to visualize biotinylated marker proteins by enhanced
chemiluminescence. Membranes were washed three times with TBS-T
and detected by enhanced chemiluminescence (Amersham).
Protocol 3: Effect of Miconazole on Response of CBF to
Glutamate
Animal Preparation
Adult (8- to 12-week-old) male Sprague-Dawley rats (Harlan,
Indianapolis, Ind) were anesthetized with 60 mg/kg body wt IP
of sodium pentobarbital (Anpro Pharmaceutical). A polyethylene cannula
(PE-240, Intramedic, Fisher Scientific) was placed into the trachea to
facilitate breathing. A femoral artery was cannulated for measurement
of systemic arterial blood pressure and withdrawal of blood
samples for monitoring arterial blood gases. Another
cannula was inserted into the femoral vein for infusion of drugs and
replacement of body fluids. Rats were administered 80 mg IP of
gallamine (Sigma) and ventilated (model 683, Harvard
Apparatus) with 30% oxygen in nitrogen. End-tidal carbon
dioxide (model Lifespan 100, Biochem International) and airway pressure
were continuously monitored. Anesthesia was supplemented at
hourly intervals or when a toe pinch resulted in an increased systemic
arterial blood pressure, with injections of 2.5 mg/kg body
wt IP of sodium pentobarbital. Rats were placed on a heating pad, and
the temperature was maintained at 37°C. After instrumentation, rats
were mounted in a Kopf stereotaxic apparatus
(model 900, David Kopf), and the scalp and connective tissue were
removed over the parietal cranial bone. An area 2 to 3 mm in
diameter was thinned in the center of the right parietal bone with a
low-speed (<8000 rpm) air drill (model Rhino XP, Midwest Dental).
Drilling was performed with a stereomicroscope until epidural and pial
vessels were visible through the closed cranial window without
penetrating the skull. Two small burr holes were drilled on opposite
sides of the window for insertion of the inflow tubing and for drainage
of excess fluid. The thin cranial plate in these two holes was
carefully removed under the microscope, and an incision was made in the
dura with care taken not to injure epidural or pial vessels. The tip of
a PE-10 polyethylene catheter pulled to a tip diameter of 200 µm
was inserted through the incision in the dura and advanced to the
border of the cranial window. The other end of the tubing was attached
to a syringe filled with aCSF by a three-way connection to allow for
simultaneous infusion of drugs into the subdural space and
measurement of inflow pressure. The distance between the tip of the
inflow tubing and the branching site of the inflow pressure tubing was
minimized to give a close estimate of local intracranial pressure. The
incision in the second hole was left open for drainage of fluids.
Flow Measurement
Cortical microvascular perfusion was monitored with a
laser-Doppler flowmeter (PF3, Perimed) and a flow probe (PF316,
"dental probe," Perimed) with a tip diameter of 1 mm. The
probe was lowered into the bottom of the cranial window with a
micromanipulator into an area devoid of visible large blood vessels and
was not moved for the duration of the experiment. A drop of mineral oil
was applied at the probe tip to provide optical coupling between the
probe and the tissue.
Experimental Protocol
After surgery, ventilation with oxygen-enriched gas mixture
(FIO2=30%) was instituted. MAP, inflow
pressure, and airway pressure were continuously monitored, and the
subdural space was perfused with aCSF at a rate that maintained inflow
pressure value between 5 and 10 mm Hg. The composition of the
aCSF mixed fresh daily was as follows (mmol/L): KCl 2.9,
MgCl2 38, CaCl2 1.99, NaCl 131.9,
NaHCO3 19, urea 6.63, glucose 3.69, with pH adjusted daily
to 7.4. The solution was prewarmed to 37°C in a water bath and
bubbled with 8% CO2 in atmospheric air for the duration of
the experiment. The laser-Doppler flow probe was positioned over
the cranial window, and laser-Doppler flow was monitored during a
30-minute stabilization period to allow for hemodynamic
stability before the experiment was started. Twice during the
experimental protocol, 0.25 mL of blood was withdrawn from the
arterial line for measurement of arterial blood
gases, arterial pH, and hemoglobin concentration (ABL-2,
Radiometer). Volume withdrawn was replaced with an equal volume of 10%
dextran 40 (Baxter) infused intravenously. After a
30-minute stabilization period, glutamate
(5x10-4 mol/L) was perfused into the subdural
space for 10 minutes at a rate of 2 µL/min. After a washout period
with aCSF for 10 minutes, the subdural space was perfused with
miconazole (20 µmol/L in aCSF) for 30 minutes, and glutamate
treatment was repeated with miconazole present at the same
time.
Data Acquisition and Analysis
MAP, laser-Doppler flow signal, inflow pressure, and airway
pressure were displayed and recorded on an eight-channel
analog-to-digital computer acquisition system (Codas, Dataq
Instruments). Control laser-Doppler flow value was calculated by
averaging laser-Doppler flow recordings over a 5-minute
period at the end of the stabilization period. Peak laser-Doppler
flow response after glutamate administration was expressed as percent
change from control, with control laser-Doppler flow taken as
100%. Laser-Doppler flow response to glutamate after miconazole
treatment was expressed as percent change of the peak laser-Doppler
flow response from a 5-minute average of steady state
recordings at the end of the 30-minute period of miconazole
treatment.
| Results |
|---|
|
|
|---|
|
|
|
|
Protocol 2: Effect of Glutamate on Expression of P-450 2C11 Protein
in Astrocytes
Fig 5
shows a representative
Western blot analysis of liver homogenates from
male and female rats and of microsomes from glutamate-treated and
untreated cultures of astrocytes using 2C11 antibody. The reactivity of
the antibody with a 55-kD band in male but not in female rat liver
demonstrates the specificity of the antibody to P-450 2C11, which is
expressed in the liver of only male rats.10 P-450 2C11 was
markedly increased in microsomes prepared from astrocytes treated with
glutamate for 24 hours compared with untreated, time-control, and
age-matched cultures with the same initial seeding density.
|
Protocol 3: Effect of Miconazole on Response of CBF to
Glutamate
A summary of physiological variables
before and after infusion of miconazole or vehicle is presented
in the Table
. MAP, arterial
PO2, PCO2, pH, and
hemoglobin were well controlled and were not altered by administration
of miconazole or vehicle.
|
Fig 6
demonstrates original tracings of
laser-Doppler flowmetry (bottom panel) and MAP (top panel)
signals during subdural administration of glutamate
(5x10-4 mol/L).
|
Fig 7
summarizes the responses of CBF to perfusion of
the subdural space with glutamate (5x10-4
mol/L) before and after miconazole treatment (20 µmol/L). CBF
increased by 64.1±12.0% before and by 9.6±1.9% after miconazole
treatment (n=5). CBF response to glutamate after perfusion with the
vehicle was not different from the value before miconazole (n=5).
|
| Discussion |
|---|
|
|
|---|
Previous work from our laboratory demonstrated that cultured astrocytes metabolize AA by the P-450 pathway to EETs and that they express P-450 2C11 cDNA.10 P-450 2C11 enzymes catalyze formation of 5,6-, 8,9-, 11,12-, and 14,15-EETs from AA.10 A physiological role for EETs in the regulation of CBF is emerging. Ellis and coworkers15 found that mouse brain tissue and cultured rat astrocytes metabolize AA to EETs, which dilate cerebral arterioles. Furthermore, inhibition of P-450 enzymes results in a 30% reduction in baseline CBF.13
The present study is an attempt to define some of the physiological variables regulating EET production and release in brain parenchymal tissue. Glutamate is a major excitatory neurotransmitter in the brain and has been implicated in cerebral vasodilation accompanying elevated neuronal activity.16 When applied through a cranial window in vivo, glutamate dilates pial arterioles.7 However, glutamate has no effect on isolated cerebral blood vessels,5 6 demonstrating that glutamate-induced enhancement of CBF may be mediated by release of dilator substances from a nonvascular cell type in the brain. Except for the neuronal specific NMDA subtype, astrocytes contain all other glutamate receptor isoforms.4 Stimulation of metabotropic glutamate receptors induces release of AA from astrocytes.9 In agreement with the latter, we found that glutamate stimulated release of AA from cultured astrocytes. The mechanism through which glutamate enhances production and release of EETs from astrocytes cannot be directly ascertained from the results of the present study; however, given the above, it could be dependent on increasing availability of substrate for P-450 epoxygenase. Other mechanisms could involve release of preformed EETs from membrane-bound pools or enhancement of enzyme activity. It is difficult to speculate on the mechanism of the increase in 2C11 protein after 12-hour exposure to glutamate; however, the fact that it is increased indicates that at least some of the glutamate-induced generation of EETs is due to the 2C11 epoxygenase isoform. At this point, we do not know if 2C11 is the only or even major P-450 epoxygenase isoform present in astrocytes.
The potential physiological significance of the above findings is highlighted by the finding that inhibition of P-450 epoxygenase activity largely inhibits the response to exogenous glutamate. Assuming for the moment that the in vivo source of epoxygenase activity lies within astrocytes, it could be speculated that spillover of glutamate during neuronal activation could stimulate release of EETs to dilate cerebral arterioles and increase blood flow to that area. More functional work will be needed to further support this hypothesis.
Activation of the neuronal NMDA receptor leads to the formation of NO by a Ca2+/calmodulindependent neuronal NO synthase pathway, leading to the hypothesis that glutamate-induced dilation is mediated by NO release through NMDA receptor activation.16 17 Several lines of evidence argue against this hypothesis. First, NMDA receptors do not appear to be involved in synaptic transmission, since selective blockade of these receptors does not affect synaptic transmission in the hippocampus despite a high abundance of NMDA receptors.18 Second, selective blockade of NMDA receptors has no effect on resting vascular tone,16 and mutant mice that do not express the gene for neuronal NO synthase demonstrate no apparent cerebrovascular pathology and exhibit an autoregulatory capacity similar to that of the wild-type animals.19 If glutamate released in the brain during synaptic activity contributes to cerebrovascular tone by activation of NMDA receptors and NO production, one would expect pharmacological blockade or genetic "knockout" of these receptors to affect resting vascular tone and blood flow.20 We have previously reported that inhibition of P-450 AA epoxygenase decreases baseline CBF without affecting responsiveness to sodium nitroprusside.13 Third, it has been demonstrated that NO released from neurons acts to enhance transmitter release from presynaptic neurons.21 Thus, NMDA-induced dilation of cerebral arteries and its attenuation by NO synthase inhibition may be related to the availability of neurotransmitters in the extracellular fluid22 rather than to the action of NMDA-evoked release of NO. In support of the latter notion is the finding that dilation of cerebral arterioles in response to nitroglycerin and nitroprusside is mediated by activation of trigeminal fibers that innervate cerebral vessels and release of calcitonin generelated peptide.23 Finally, activation of the quisqualate (AMPA) receptor subtype also leads to the release of NO from neurons24 25 26 but, in contrast to NMDA and kainate glutamate receptors subtypes, fails to dilate cerebral vessels.
In summary, we have presented evidence to support the hypothesis that glutamate-induced dilation of cerebral arterioles is mediated at least in part by changes in the formation and release of EETs by astrocytes. The close proximity of astrocytes to both synaptic clefts and cerebral microvessels makes a neurotransmitter-sensitive release of a vasodilator substance a plausible mechanism to couple neuronal activity to regional increases in CBF.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received October 29, 1996; revision received January 29, 1997; accepted January 30, 1997.
| References |
|---|
|
|
|---|
2.
Kuschinsy W. Coupling of function,
metabolism, and blood flow in the brain. News
Physiol Sci. 1987;2:217-220.
3. Idecola C, Pelligrino DA, Moskowitz MA, Lassen NA. Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow Metab. 1994;14:175-192.[Medline] [Order article via Infotrieve]
4.
Hansson E, Rönnbäck L. Astrocytes
in glutamate neurotransmission. FASEB J. 1995;9:343-350.
5. Hardebo JE, Wieloch T, Kåhrström J. Excitatory amino acids and cerebrovascular tone. Acta Physiol Scand. 1989;136:483-485.[Medline] [Order article via Infotrieve]
6. Takayasu M, Dacey RG. Effects of inhibitory and excitatory amino acid neurotransmitters on isolated cerebral parenchymal arterioles. Brain Res. 1989;482:393-396.[Medline] [Order article via Infotrieve]
7.
Busija DW, Leffler CW. Dilator effect of amino
acid neurotransmitter on piglet pial arterioles. Am
J Physiol. 1989;257:H1200-H1203.
8. Gallo V, Russel JT. Excitatory amino acid receptors in glia: different subtypes for distinct functions? J Neurosci Res. 1995;42:1-8.[Medline] [Order article via Infotrieve]
9. Stella N, Tencé M, Glowinski J, Prémont J. Glutamate-evoked release of arachidonic acid from mouse brain astrocytes. J Neurosci. 1994;14:568-575.[Abstract]
10.
Alkayed NJ, Narayanan J, Gebremedhin D, Medhora M,
Roman RJ, Harder DR. Molecular characterization of an
arachidonic acid epoxygenase in rat brain
astrocytes. Stroke. 1996;27:971-979.
11.
Gebremedhin D, Ma Y-H, Falck JR, Roman RJ, VanRollins
M, Harder DR. Mechanism of action of cerebral
epoxyeicosatrienoic acids on cerebral arterial smooth
muscle. Am J Physiol. 1992;263:H519-H525.
12. Hu S, Kim H. Activation of K+ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. Eur J Pharmacol. 1993;230:215-221.[Medline] [Order article via Infotrieve]
13.
Alkayed NJ, Birks EK, Hudetz AG, Roman RJ, Henderson L,
Harder DR. Inhibition of brain P450 arachidonic
acid epoxygenase decreases baseline cerebral blood
flow. Am J Physiol. 1996;271:H1541-H1546.
14. Hansson E, Rönnbäck L. Primary cultures of astroglia and neurons from different brain regions. In: Shahar A, de Vellis J, Vernadakis A, Haber B, eds. A Dissection and Tissue Culture Manual of the Nervous System. New York, NY: Alan R. Liss, Inc; 1989;92-104.
15. Ellis EF, Police RJ, Yancey L, McKinney JS, Amruthesh SC. Dilation of cerebral arterioles by cytochrome P-450 metabolites of arachidonic acid. Am J Physiol. 1990;259(Heart Circ Physiol. 28):H1171-H1177.
16.
Meng W, Tobin JR, Busija DW. Glutamate-induced
cerebral vasodilation is mediated by nitric oxide through
N-methyl-D-aspartate receptors.
Stroke. 1995;26:857-863.
17.
Faraci FM, Breese KR. Nitric oxide mediates
vasodilation in response to activation of
N-methyl-D-aspartate receptors in brain.
Circ Res. 1993;72:476-480.
18. Morris RGM, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 1986;319:774-776.[Medline] [Order article via Infotrieve]
19.
Huang Z, Huang PL, Panahian N, Dalkara T, Fishman
MC, Moskowitz MA. Effects of cerebral ischemia in mice
deficient in neuronal nitric oxide synthase.
Science. 1994;265:1883-1885.
20. Idecola C. Editorial comment on: Meng W, Tobin JR, Busija DW. Glutamate-induced cerebral vasodilation is mediated by nitric oxide through N-methyl-D-aspartate receptors. Stroke. 1995;26:857-863.
21.
Scuman EM, Madison DV. A requirement for the
intracellular messenger nitric oxide in long term potentiation.
Science. 1991;254:1503-1506.
22. Ghribi O, Callebert J, Plotkine M, Boulu RG. L-NAME modulates glutamate accumulation induced by K+-depolarization but not by forebrain ischaemia in the rat striatum. Neurosci Lett. 1994;174:34-38.[Medline] [Order article via Infotrieve]
23.
Wei EP, Moskowitz MA, Boccalini P, Kontos HA.
Calcitonin gene-related peptide mediates nitroglycerin
and sodium nitroprusside-induced vasodilation in feline cerebral
arterioles. Circ Res. 1992;70:1313-1319.
24. Wood PL, Emmett MR, Rao TS, Cler J, Mick S, Iyengar S. Inhibition of nitric oxide synthase blocks N-methyl-D-aspartate-, quisqualate-, kainate-, harmaline-, and pentylenetetrazole-dependent increases in cerebellar cyclic GMP in vivo. J Neurochem. 1990;55:346-348.[Medline] [Order article via Infotrieve]
25. Southam E, East SJ, Garthwaite J. Excitatory amino acid receptors coupled to the nitric oxide/cyclic GMP pathway in rat cerebellum during development. J Neurochem. 1991;56:2072-2081.[Medline] [Order article via Infotrieve]
26. Okada D. Two pathways of cyclic GMP production through glutamate receptor-mediated nitric oxide synthesis. J Neurochem. 1992;59:1203-1210.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
K. R. Chaudhary, S. N. Batchu, D. Das, M. R. Suresh, J. R. Falck, J. P. Graves, D. C. Zeldin, and J. M. Seubert Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function Cardiovasc Res, July 15, 2009; 83(2): 362 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Iliff, R. Wang, D. C. Zeldin, and N. J. Alkayed Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1352 - H1363. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, C. Li, J. R. Falck, R. J. Roman, D. R. Harder, and R. C. Koehler Interaction of nitric oxide, 20-HETE, and EETs during functional hyperemia in whisker barrel cortex Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H619 - H631. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sura, R. Sura, A. E. EnayetAllah, and D. F. Grant Distribution and Expression of Soluble Epoxide Hydrolase in Human Brain J. Histochem. Cytochem., June 1, 2008; 56(6): 551 - 559. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Blanco, J. E. Stern, and J. A. Filosa Tone-dependent vascular responses to astrocyte-derived signals Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2855 - H2863. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Iliff, L. N. Close, N. R. Selden, and N. J. Alkayed A novel role for P450 eicosanoids in the neurogenic control of cerebral blood flow in the rat Exp Physiol, July 1, 2007; 92(4): 653 - 658. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Haydon and G. Carmignoto Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev, July 1, 2006; 86(3): 1009 - 1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ayata and M. A. Moskowitz Cortical spreading depression confounds concentration-dependent pial arteriolar dilation during N-methyl-D-aspartate superfusion Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1837 - H1841. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Koehler, D. Gebremedhin, and D. R. Harder Role of astrocytes in cerebrovascular regulation J Appl Physiol, January 1, 2006; 100(1): 307 - 317. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. You, E. M. Golding, and R. M. Bryan Jr. Arachidonic acid metabolites, hydrogen peroxide, and EDHF in cerebral arteries Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1077 - H1083. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Jung, R. P. Brandes, I.-H. Kim, F. Schweda, R. Schmidt, B. D. Hammock, R. Busse, and I. Fleming Soluble Epoxide Hydrolase Is a Main Effector of Angiotensin II-Induced Hypertension Hypertension, April 1, 2005; 45(4): 759 - 765. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Fellin and G. Carmignoto Neurone-to-astrocyte signalling in the brain represents a distinct multifunctional unit J. Physiol., August 15, 2004; 559(1): 3 - 15. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Iliff, R. D'Ambrosio, A. C. Ngai, and H. R. Winn Adenosine receptors mediate glutamate-evoked arteriolar dilation in the rat cerebral cortex Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1631 - H1637. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gebremedhin, K. Yamaura, C. Zhang, J. Bylund, R. C. Koehler, and D. R. Harder Metabotropic Glutamate Receptor Activation Enhances the Activities of Two Types of Ca2+-Activated K+ Channels in Rat Hippocampal Astrocytes J. Neurosci., March 1, 2003; 23(5): 1678 - 1687. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zhang and D. R. Harder Cerebral Capillary Endothelial Cell Mitogenesis and Morphogenesis Induced by Astrocytic Epoxyeicosatrienoic Acid Stroke, December 1, 2002; 33(12): 2957 - 2964. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Peng, J. R. Carhuapoma, A. Bhardwaj, N. J. Alkayed, J. R. Falck, D. R. Harder, R. J. Traystman, and R. C. Koehler Suppression of cortical functional hyperemia to vibrissal stimulation in the rat by epoxygenase inhibitors Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H2029 - H2037. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Alkayed, T. Goyagi, H.-D. Joh, J. Klaus, D. R. Harder, R. J. Traystman, and P. D. Hurn Neuroprotection and P450 2C11 Upregulation After Experimental Transient Ischemic Attack Stroke, June 1, 2002; 33(6): 1677 - 1684. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Roman P-450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function Physiol Rev, January 1, 2002; 82(1): 131 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Fleming Cytochrome P450 and Vascular Homeostasis Circ. Res., October 26, 2001; 89(9): 753 - 762. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Rodriguez, K. Mackie, and V. M. Pickel Ultrastructural Localization of the CB1 Cannabinoid Receptor in {micro}-Opioid Receptor Patches of the Rat Caudate Putamen Nucleus J. Neurosci., February 1, 2001; 21(3): 823 - 833. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bhardwaj, F. J. Northington, J. R. Carhuapoma, J. R. Falck, D. R. Harder, R. J. Traystman, and R. C. Koehler P-450 epoxygenase and NO synthase inhibitors reduce cerebral blood flow response to N-methyl-D-aspartate Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1616 - H1624. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Thompson, J. H. Capdevila, and H. W. Strobel Recombinant Cytochrome P450 2D18 Metabolism of Dopamine and Arachidonic Acid J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1120 - 1130. [Abstract] [Full Text] |
||||
![]() |
D. Zhu, M. Bousamra II, D. C. Zeldin, J. R. Falck, M. Townsley, D. R. Harder, R. J. Roman, and E. R. Jacobs Epoxyeicosatrienoic acids constrict isolated pressurized rabbit pulmonary arteries Am J Physiol Lung Cell Mol Physiol, February 1, 2000; 278(2): L335 - L343. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Rzigalinski, K. A. Willoughby, S. W. Hoffman, J. R. Falck, and E. F. Ellis Calcium Influx Factor, Further Evidence It Is 5,6-Epoxyeicosatrienoic Acid J. Biol. Chem., January 1, 1999; 274(1): 175 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Harder, N. J. Alkayed, A. R. Lange, D. Gebremedhin, and R. J. Roman Functional Hyperemia in the Brain : Hypothesis for Astrocyte-Derived Vasodilator Metabolites Stroke, January 1, 1998; 29(1): 229 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Domoki, J. V. Perciaccante, K. Shimizu, M. Puskar, D. W. Busija, and F. Bari N-methyl-D-aspartate-induced vasodilation is mediated by endothelium-independent nitric oxide release in piglets Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1404 - H1409. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |